Dr. Reddy’s Announces the Launch of Quetiapine Fumarate Tablets

HYDERABAD, India--()--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Quetiapine fumarate tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg), a bioequivalent generic version of SEROQUEL® tablets in the US market on March 27, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Quetiapine fumarate tablets.

The SEROQUEL® brand had U.S. sales of approximately $4.6 billion for the most recent twelve months ending December 2011 according to IMS Health.

Dr. Reddy’s Quetiapine fumarate tablets in 25 mg and 50 mg are available in 100 and 500 count bottle sizes, 100 mg, 200 mg and 400 mg are available in 100 count bottle sizes and 300 mg is available in 60 count bottle sizes.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, Custom Pharmaceutical Services, Generics, Biosimilars, Differentiated Formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com.

SEROQUEL® tablets are a registered trademark of AstraZeneca UK Limited.

IMS National Sales Perspectives: Retail and Non-Retail MAT December 2011

Contacts

Dr. Reddy’s Laboratories
Investors and Financial Analysts:
Kedar Upadhye
+91-40-66834297
kedaru@drreddys.com
or
Raghavender R
+91-40-49002135
raghavenderr@drreddys.com
or
Milan Kalawadia (USA)
+1-908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan
+91-40-49002445
rajans@drreddys.com

Sharing

Contacts

Dr. Reddy’s Laboratories
Investors and Financial Analysts:
Kedar Upadhye
+91-40-66834297
kedaru@drreddys.com
or
Raghavender R
+91-40-49002135
raghavenderr@drreddys.com
or
Milan Kalawadia (USA)
+1-908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan
+91-40-49002445
rajans@drreddys.com